These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 15283547)
21. Don't pay too much for generic fills. Pass-through pricing is a good way for a payer to realize the benefit of increased prescribing of generic drugs. Cahn LJ Manag Care; 2010 Nov; 19(11):21-7. PubMed ID: 21141372 [No Abstract] [Full Text] [Related]
22. The cost of prescription drugs: rising concerns over equity, fairness and access to essential care. Work DR; Domino ME N C Med J; 2003; 64(6):270-4. PubMed ID: 14983614 [No Abstract] [Full Text] [Related]
23. Rebates and other drug-cost issues. Penna P Manag Care Interface; 2003 May; 16(5):39-40. PubMed ID: 12789863 [No Abstract] [Full Text] [Related]
24. Why drugs cost so much. Noonan D Newsweek; 2000 Sep; 136(13):22-30. PubMed ID: 11183315 [No Abstract] [Full Text] [Related]
25. Supply and demand: negotiating the prescription drug labyrinth to reduce costs. DeStefino K Benefits Q; 2003; 19(1):30-7. PubMed ID: 12608116 [TBL] [Abstract][Full Text] [Related]
26. Healing an ailing pharmaceutical system: prescription for reform for United States and Canada. Gaffney A; Lexchin J; ; BMJ; 2018 May; 361():k1039. PubMed ID: 29773533 [No Abstract] [Full Text] [Related]
27. The UK House of Commons report on the influence of the pharmaceutical industry: lessons for equitable access to medicines in Australia. Faunce TS; Tomossy GF Monash Bioeth Rev; 2005 Apr; 24(2):38-42. PubMed ID: 16208881 [TBL] [Abstract][Full Text] [Related]
28. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004. Seay M Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309 [No Abstract] [Full Text] [Related]
29. Rumble Over Drug Rebates As Pharma, Payers Duke It Out. Reinke T Manag Care; 2018 Oct; 27(10):10-11. PubMed ID: 30309442 [TBL] [Abstract][Full Text] [Related]
30. Dilemmas in regulation of the market for pharmaceuticals. Maynard A; Bloor K Health Aff (Millwood); 2003; 22(3):31-41. PubMed ID: 12757269 [TBL] [Abstract][Full Text] [Related]
31. Drugs: budget busters or cost cutters in future health care? Egger E Health Care Strateg Manage; 1999 Mar; 17(3):1, 22-3. PubMed ID: 10351640 [No Abstract] [Full Text] [Related]
32. Pricing in the Market for Anticancer Drugs. Howard DH; Bach PB; Berndt ER; Conti RM J Econ Perspect; 2015; 29(1):139-62. PubMed ID: 28441702 [No Abstract] [Full Text] [Related]
33. Makers of anticancer drugs are "profiteering," say 100 specialists from around the world. Laurance J BMJ; 2013 Apr; 346():f2810. PubMed ID: 23633224 [No Abstract] [Full Text] [Related]
38. Congress has its brain on drug benefits. Birnbaum JH Fortune; 2003 Jan; 147(1):178. PubMed ID: 12602124 [No Abstract] [Full Text] [Related]
39. Pharmacy benefit management: the right Rx? Etheredge L Res Agenda Brief; 1995 Apr; (1):1-11. PubMed ID: 12856664 [No Abstract] [Full Text] [Related]
40. Maximum allowable cost: can the government control drug costs? Smith MI; Wertheimer AI J Health Polit Policy Law; 1979; 4(2):155-75. PubMed ID: 385712 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]